Product Name
PCSK9, siRNA
Full Product Name
PCSK9 siRNA (Mouse)
Product Synonym Names
NARC1; Proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9
Product Gene Name
PCSK9 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q80W65
Specificity
PCSK9 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse PCSK9 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of PCSK9 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
PCSK9 sirna
siRNA to inhibit PCSK9 expression using RNA interference
Applications Tested/Suitable for PCSK9 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for PCSK9. It may not necessarily be applicable to this product.
NCBI Accession #
NP_705793.1
[Other Products]
NCBI GenBank Nucleotide #
NM_153565.2
[Other Products]
UniProt Primary Accession #
Q80W65
[Other Products]
UniProt Secondary Accession #
Q3UEH7; Q8BXW9; Q8CFT6; B1AZI4[Other Products]
UniProt Related Accession #
Q80W65[Other Products]
Molecular Weight
74,823 Da
NCBI Official Full Name
proprotein convertase subtilisin/kexin type 9
NCBI Official Synonym Full Names
proprotein convertase subtilisin/kexin type 9
NCBI Official Symbol
Pcsk9??[Similar Products]
NCBI Official Synonym Symbols
FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682
??[Similar Products]
NCBI Protein Information
proprotein convertase subtilisin/kexin type 9
UniProt Protein Name
Proprotein convertase subtilisin/kexin type 9
UniProt Synonym Protein Names
Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9
Protein Family
Proprotein convertase subtilisin/kexin
UniProt Gene Name
Pcsk9??[Similar Products]
UniProt Synonym Gene Names
Narc1; NARC-1; PC9??[Similar Products]
UniProt Entry Name
PCSK9_MOUSE
UniProt Comments for PCSK9
PCSK9: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Defects in PCSK9 are the cause of hypercholesterolemia autosomal dominant type 3 (HCHOLA3). A familial condition characterized by elevated circulating cholesterol contained in either low-density lipoproteins alone or also in very-low-density lipoproteins. Belongs to the peptidase S8 family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Secreted; Protease; EC 3.4.21.-; Cell development/differentiation; Secreted, signal peptide
Cellular Component: Golgi apparatus; extracellular space; cell surface; rough endoplasmic reticulum; lysosome; endoplasmic reticulum; early endosome; extracellular region; ER to Golgi transport vesicle; perinuclear region of cytoplasm; late endosome; cytoplasm; plasma membrane; endosome
Molecular Function: peptidase activity; very-low-density lipoprotein binding; sodium channel inhibitor activity; protein self-association; low-density lipoprotein receptor binding; hydrolase activity; serine-type peptidase activity; serine-type endopeptidase activity; low-density lipoprotein binding; apolipoprotein binding; apolipoprotein receptor binding
Biological Process: steroid metabolic process; cholesterol metabolic process; lysosomal transport; apoptosis; positive regulation of receptor internalization; lipoprotein metabolic process; regulation of low-density lipoprotein receptor catabolic process; proteolysis; cellular response to starvation; neuron differentiation; protein autoprocessing; cholesterol homeostasis; triacylglycerol metabolic process; cellular response to insulin stimulus; phospholipid metabolic process; positive regulation of neuron apoptosis; regulation of neuron apoptosis; low-density lipoprotein receptor catabolic process; negative regulation of receptor recycling; protein processing; regulation of receptor activity; lipid metabolic process; low-density lipoprotein receptor metabolic process
Research Articles on PCSK9
1. reduced PCSK9 function is associated with increased pathogen lipid clearance.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
